Jyong Biotech (MENS) Current Assets (2024 - 2025)
Jyong Biotech's (MENS) quarterly Current Assets came in at $15.5 million in Q4 2025, up 7444.66% year-on-year from $206000.0 in Q4 2024, and down 9.44% quarter-over-quarter from $17.2 million in Q2 2025.
Jyong Biotech (MENS) Current Assets (2024 - 2025) Analysis & Trends
Jyong Biotech's Current Assets history runs 2 years deep, the most recent figure standing at $15.5 million for Q4 2025.
- On a quarterly basis, Current Assets rose 7444.66% year-over-year to $15.5 million in Q4 2025; TTM through Dec 2025 was $15.5 million, a 7444.66% increase from a year earlier, with the FY2025 full-year figure at $15.5 million, up 7444.66% from the prior year.
- Current Assets slipped to $15.5 million in Q4 2025 per MENS's latest filing, from $17.2 million in the prior quarter.
- Across five years, Current Assets topped out at $17.2 million in Q2 2025 and bottomed at $206000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 73.04 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 6.60 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 8.07 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.97 Bn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 15.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.54 Mn |
| Jun 30, 2025 | 17.16 Mn |
| Dec 31, 2024 | 206,000.00 |